secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001619856-25-000002
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences appoints Sri Ryali as CFO, effective January 2, 2025
------------------------------------------------------------------------

- Sri Ryali named CFO; brings 20 years biopharma finance experience; most recently CFO of Codexis.
- Ryan Fischesser ceases as interim principal financial officer and accounting officer; remains VP Finance.
- Ryali receives $485k base salary, 40% target bonus, and option to purchase 300k shares vesting over 4 years.
- Company highlights four clinical-stage programs for hematologic malignancies and autoimmune diseases; expects multiple datasets in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000002/0001619856-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000002/crbu-20250102.htm
  HTML page:      https://secwatch.observer/filing/0001619856-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer